The focal point of the lawsuit was the development and marketing of BioVie's flagship product, [specific drug name]. Investors argued that the company provided overly optimistic projections about the drug's potential and downplayed risks associated with its development. As a result, shareholders claimed to have invested based on misleading information, leading to financial losses when the truth...